Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06652958 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

A Phase 1 study of HIV Infections, sponsored by ViiV Healthcare.

Active
Registry status
Phase 1
Development phase
102
Enrollment target
1
Study location

NCT06652958 is a Phase 1 study of HIV Infections that is active but no longer recruiting, run by ViiV Healthcare. The registered enrollment target is 102 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06652958, a Phase 1 study of HIV Infections, is active but no longer recruiting, sponsored by ViiV Healthcare.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Persons with HIV (PWH).

Conditions Studied

Interventions

  • BIOLOGICAL VH4527079

Study Locations (1)

Nevada

  • GSK Investigational Site - Las Vegas

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2024-10-02
Est. Completion 2026-09-09
Phase Phase 1

Sponsor

ViiV Healthcare

182 total trials

What the Registry Record Tells You About NCT06652958

The ClinicalTrials.gov registry entry for NCT06652958 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (77% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which VH4527079 is the first listed.

NCT06652958 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT06652958 about?

NCT06652958 is a clinical study titled "A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV". This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Pers...

What is the current status of trial NCT06652958?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2024-10-02. Estimated completion is 2026-09-09.

What conditions does trial NCT06652958 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT06652958?

The interventions under investigation include: VH4527079 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06652958?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06652958 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.